CLINICAL TRIALS PROFILE FOR HYDROGEN PEROXIDE

505(b)(2) Clinical Trials for Hydrogen Peroxide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT07356271 ↗	Effects of Mouthwashes on the Oral Microbiome and Systemic Health	NOT_YET_RECRUITING	University of Plymouth	EARLY_PHASE1	2026-02-01	OVERVIEW While antimicrobial mouthwashes are proven to be clinically effective for management of certain oral microbial diseases, recent studies (Bescos et al 2025, Gallard et al 2025) suggest tha, in addition to targeting bacteria responsible for gum diseases such as gingivitis and periodontitis, they may harm healthy bacteria and disturb the balance and protective role of the oral microbiome (dysbiosis). Most findings on the oral microbiome and mouthwashes involve chlorhexidine use, demonstrating that it may induce dysbiosis and compromise the host oral microenvironment (Bescos et al 2020). A recent study completed in 2025 (Gallardo et al 2025) has shown that CPC mouthwash can also inhibit nitrate synthesis in the mouth. However there remains a need for further research on other agents used in mouthrinses, such as hydrogen peroxide, essential oils, or saline mouthwashes, to determine whether their clinical effectiveness in managing oral disease is accompanied by changes to the oral microbiome. In dentistry, despite this being the place where most people are treated, there are very few research studies that have been performed in primary care settings. Hence this study will be designed for delivery in primary care, to produce 'real-life' data on a patient cohort more typical of general dental practice. This PhD project will select several of the most commonly used over the counter (OTC) mouthwash constituents, used by the general public, that have a limited evidence base, regarding their effects on the oral microbiome in vivo. The first agent to be studied is physiological saline (sodium chloride), as this is the mouthwash advised by dental guidelines for use after tooth extractions, yet there is little evidence to support this approach. No previous studies have previously quantified its effects on clinical outcomes and the oral microbiome. All mouthwashes will be tested in people with, or without, gum disease (gingivitis and periodontitis) to determine which interventions are best used in either health or disease.

All Clinical Trials for Hydrogen Peroxide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00154635 ↗	Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease	Unknown status	Development Center for Biotechnology, Taiwan	Phase 2	2005-09-01	A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗	Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease	Unknown status	Program Office, National Science & Technology, Biotechnology & Pharmaceuticals	Phase 2	2005-09-01	A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗	Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease	Unknown status	Taipei Veterans General Hospital, Taiwan	Phase 2	2005-09-01	A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗	Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease	Unknown status	National Taiwan University Hospital	Phase 2	2005-09-01	A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.

Clinical Trial Conditions for Hydrogen Peroxide

Condition Name

Condition Name for Hydrogen Peroxide
Intervention	Trials
Covid-19	6
Tooth Discoloration	6
Covid19	4
Tooth Sensitivity	4

Condition MeSH

Condition MeSH for Hydrogen Peroxide
Intervention	Trials
COVID-19	10
Dentin Sensitivity	10
Tooth Discoloration	8
Hypersensitivity	7

Clinical Trial Locations for Hydrogen Peroxide

Trials by Country

Trials by Country for Hydrogen Peroxide
Location	Trials
United States	50
Brazil	11
Egypt	10
United Kingdom	6
Australia	5

Trials by US State

Trials by US State for Hydrogen Peroxide
Location	Trials
California	8
Texas	5
Tennessee	4
New York	4
Pennsylvania	3

Clinical Trial Progress for Hydrogen Peroxide

Clinical Trial Phase

Clinical Trial Phase for Hydrogen Peroxide
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	3
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Hydrogen Peroxide
Clinical Trial Phase	Trials
Completed	54
Not yet recruiting	19
Recruiting	17

Clinical Trial Sponsors for Hydrogen Peroxide

Sponsor Name

Sponsor Name for Hydrogen Peroxide
Sponsor	Trials
Colgate Palmolive	4
Universidade Estadual de Ponta Grossa	3
Ain Shams University	3

Sponsor Type

Sponsor Type for Hydrogen Peroxide
Sponsor	Trials
Other	136
Industry	24
NIH	2

Hydrogen Peroxide (Drug): Clinical Trials Update, Market Analysis, and Projection

Last updated: April 26, 2026

What is hydrogen peroxide used for in medicine?

Hydrogen peroxide (H₂O₂) is used clinically as a topical antiseptic/antimicrobial in wound care and as an oral/OTC dental antiseptic in some formulations. In mainstream global clinical-trial registries, hydrogen peroxide is overwhelmingly represented as a legacy active ingredient in non-oncology, local-treatment settings, most often in topical forms rather than as a systemically developed “drug product” with large Phase 2/3 programs.

Because “HYDROGEN PEROXIDE” is also widely sold as an antiseptic OTC product (and as industrial-grade solutions), the clinical and market record is fragmented by formulation strength, route (topical/oral/irrigation), and medical device-adjacent use (wound-care systems). A “drug” market for hydrogen peroxide therefore tracks mostly off-label or formulation-specific clinical evidence and regulated product categories rather than a single modern blockbuster development pipeline.

What clinical trial activity exists for hydrogen peroxide right now?

No single, consolidated, high-volume global program stands out for hydrogen peroxide as a new molecular entity with broad Phase 2-3 registration activity. Trial activity typically appears as:

• Topical antiseptic comparisons (standard of care vs hydrogen peroxide-based regimens)
• Wound-care protocols (irrigation/cleaning steps)
• Dental/oral antisepsis trials (mouth rinses/locally applied peroxide formulations)
• Device-linked or regimen-linked studies (peroxide delivered as part of a wound-care system)

Clinical-trials update method used: clinical evidence is compiled from public registries (clinicaltrials.gov and major international trial registries) and filtered for interventional studies that explicitly involve “hydrogen peroxide” as an administered intervention.

Current state (high-level):

• Hydrogen peroxide shows episodic trial reporting rather than continuous, large-scale Phase 3 registrational programs.
• Studies skew toward local antisepsis and care-protocol optimization rather than systemic disease modification.

What does the pipeline look like by phase?

Public records for hydrogen peroxide largely reflect earlier-stage or smaller comparative interventional work rather than multi-region Phase 2-3 pivotal programs. Where later-phase trials exist, they often relate to specific indications and formulations rather than a unified development thesis.

Development attribute	Observed pattern for H₂O₂ in registries	Business implication
Phase distribution	Mostly small comparative studies; fewer large late-phase programs	Lower likelihood of near-term “registrational step-change”
Indication cluster	Wound care, dental/oral antisepsis, topical infection control	Market is indication-by-indication and product-by-product
Product type	Topical/oral solutions and regimen-linked formulations	Regulatory strategy depends on formulation and claim scope
Geography	Patchy; tends to be country/site-specific	Commercial scale depends on local approvals and channel access

What trial outcomes are typically evaluated?

Hydrogen peroxide studies typically measure endpoints aligned with antimicrobial and wound healing effects:

• Reduction in microbial load or infection rates
• Healing metrics (time to closure, wound size reduction)
• Pain/comfort tolerability during treatment
• Adverse events related to local irritation and tissue effects

These outcomes tend to support product differentiation via regimen performance rather than disease-course redesign.

---

How big is the hydrogen peroxide market in healthcare?

Hydrogen peroxide is a commoditized chemical with a very large global consumption base in industrial and consumer uses. The healthcare “drug-like” market is smaller and depends heavily on:

• Regulatory category (OTC antiseptic, prescription antiseptic, wound-care product)
• Concentration and formulation (stabilized solutions, buffered forms, controlled-release variants)
• Packaging and labeling (wound cleaning vs oral rinsing vs device-associated delivery)

As a result, market sizing must be approached through healthcare antiseptic segments rather than the full global chemical market.

Reference points (chemical and broader usage context):

• Hydrogen peroxide is produced and used at industrial scale globally, indicating extensive supply and price competition.
• The consumer/medical antiseptic ecosystem also benefits from established distribution channels, which compresss margins.

For investment and R&D planning, the key practical assumption is that hydrogen peroxide competes more like a specialty antiseptic commodity than like a protected branded small molecule.

---

What competitive landscape dominates?

Is the market protected by patents?

Hydrogen peroxide itself is not patent-protected as a composition of matter in any durable, modern sense. The practical exclusivity levers are usually:

• Formulation stabilization (buffering, stabilizers, controlled release)
• Delivery system integration (wound-care device kits, application systems)
• Specific labeled indications and dosing/regimen claims
• Manufacturing process improvements for medical-grade products

This leads to:

• Many low-cost entrants
• Competition on packaging, claim language, and local regulatory approvals

Who competes?

Competition typically includes:

• Other topical antiseptics (povidone-iodine, chlorhexidine, benzalkonium chloride, hypochlorous acid products)
• Hydrogen peroxide alternatives in wound-care and oral care
• Generics in peroxide formulations where available

---

What is the demand driver stack?

Demand drivers

• Ongoing need for wound cleansing and infection prevention in chronic wounds, post-procedural care, and minor injuries
• Continued preference by some formularies for peroxide-based regimens due to cost and availability
• Growth in home care and outpatient wound management (channel expansion)

Constraints

• Safety and tolerability concerns associated with higher concentration or improper use
• Shifts toward antiseptics with broader guideline adoption in some settings
• Regulatory scrutiny around claims, concentration, and labeling

---

How should the hydrogen peroxide market be segmented for projection?

Hydrogen peroxide healthcare usage can be projected by the segments where it is actually used as an antiseptic product:

Segment	Typical setting	Primary value driver	Typical buying entity
Wound care antisepsis (topical)	Acute minor wounds, wound cleaning protocols, some chronic wound regimens	Clinical protocol fit and procurement cost	Hospitals, clinics, wound-care providers
Oral/dental antisepsis	Mouth rinses, oral antiseptic regimens (where authorized)	Tolerability, claims, and patient adherence	Pharmacies, dental channel
Device-associated peroxide systems	Kits and delivery systems that include peroxide	Ease of use and bundled workflow	Hospitals, med supply distributors

Projection accuracy depends on local authorization and channel penetration rather than on a single global “drug” adoption curve.

---

Clinical trials update: what is most actionable?

For an R&D or investment decision, the most actionable insight is that hydrogen peroxide’s clinical evidence base is likely to support niche, formulation-level differentiation rather than a large new systemic indication.

Where value is likely to concentrate

• Stabilized formulations that reduce irritation while preserving antimicrobial activity
• Clear, label-supported regimen claims tied to endpoints like infection reduction or wound outcomes
• Device-integrated peroxide delivery with standardized application workflows

Where value is less likely

• Systemic disease indications
• Large-scale global late-phase development where the active is already commoditized and switching costs are low

---

Market projection: base-case view (directional, segment-led)

Given the lack of a single unified late-phase registrational pipeline, projections should be built on:

• Incremental growth in healthcare antiseptic utilization
• Replacement dynamics vs competing antiseptics
• Price erosion typical of commodity-adjacent products
• Uptake constrained by safety/tolerability positioning and guideline shifts

Three-scenario framework (directional)

Scenario	Assumptions	Resulting growth profile
Conservative	Continued price pressure; limited claim expansion; antiseptic guideline shift away in some settings	Flat-to-slow growth
Base case	Moderate channel growth; incremental formulation differentiation; stable procurement	Low-to-mid single digit growth
Upside	Expanded label claims in wound and oral care; stronger guideline alignment; device bundling traction	Higher single digit growth

This framework is consistent with how peroxide-based antiseptics tend to behave commercially: steady demand with limited differentiation and frequent pricing compression.

---

Regulatory and patent strategy implications

Because hydrogen peroxide is not a protected new molecular entity, the competitive moat usually comes from:

• Formulation patents (where available) and manufacturing process IP
• Data packages that support specific claims
• Regulatory submissions for medical product classification (OTC vs prescription; device combo products; concentration and labeling controls)

This pushes development toward:

• Comparative clinical evidence for a specific product/formulation and use protocol
• Clear endpoint strategy aligned to antimicrobial action and tolerability

---

Key Takeaways

• Hydrogen peroxide clinical trial activity is present but typically episodic and formulation/regimen-specific, with a heavier tilt toward topical antisepsis rather than large systemic development programs.
• The commercial landscape is commoditized and price-competitive; sustainable advantage usually requires formulation, delivery, labeling, and protocol differentiation, not novel active ingredient IP.
• Market projections should be built segment-led (wound care, oral antisepsis, device-linked systems) using replacement and procurement dynamics, not a single blockbuster adoption curve.

---

FAQs

1. Is hydrogen peroxide being developed like a modern prescription drug with global Phase 3 programs?
   Most public evidence reflects topical/oral antisepsis use and smaller comparative studies rather than unified, large late-phase registrational programs.

2. What endpoints matter most in hydrogen peroxide clinical studies?
   Trials commonly focus on antimicrobial or infection-related outcomes, wound healing metrics, and local tolerability.

3. Why is market growth constrained for hydrogen peroxide as a “drug”?
   Hydrogen peroxide is widely available and generally treated as a commodity active, leading to pricing pressure and limited long-term exclusivity.

4. Where can companies build differentiation?
   Stabilized formulations, controlled release or standardized application systems, and tightly scoped, label-backed claims.

5. How should investors project demand?
   Use segment and channel assumptions (hospital wound care purchasing, outpatient/home-care adoption, oral care retail/dental channel) with scenario-based pricing and substitution effects.

---

References (APA)

1. U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
2. World Intellectual Property Organization. (n.d.). WIPO PATENTSCOPE. https://patentscope.wipo.int/
3. International Trade Centre. (n.d.). Trade Map: Hydrogen peroxide (HS codes). https://www.trademap.org/
4. U.S. Food and Drug Administration. (n.d.). Drug approvals and regulatory information (topical/oral antiseptic context). https://www.fda.gov/drugs